Medical network September 6, as of August 31, 194 listed pharmaceutical manufacturing enterprises (SFC) in Shanghai and shenzhen have fully disclosed the financial data of the first half of the year. In the first half of this year, 194 pharmaceutical manufacturing enterprises realized total revenue of RMB 300745 million. Net profit was 39.707 billion yuan. Below, small make up from operating income, revenue growth, net profit, net profit margin, sales gross interest rate several dimensions to analyze, look at the first half year of 2017 which performance is most eye-catching!
The market overview
In the first half of the year, the revenues and profits of the company showed a better trend, with total revenue reaching 300745 million yuan. Net profit was 39.707 billion yuan. On the profit side, 96.91% of the first half of the year realized positive earnings.
First half list
Operating income Top20
In the first half of the year, China's pharmaceutical business revenue was 14.09 billion yuan, ranking first in the listed pharmaceutical companies in a-share market. Kangmei pharmaceutical, with 13.26 billion yuan, ranked second. Twenty of the top 20 companies have been taken up by chemical pharmaceuticals and Chinese medicine.
Revenue growth TOP20
In the first half of the year, 647% of its revenues rose to the top of the annual growth rate, with only five listed companies growing more than double.
Profit TOP20
Pharmaceutical industry net profit of 2.15 billion yuan in the first half of the sig, ranked the TOP net TOP, fosun medicine net profit of 1.689 billion yuan, ranked second, hengrui pharmaceutical on $1.573 billion, followed by a third. In the list of net profit, there are 11 companies in the middle of the pharmaceutical industry, making up half of the high profit list, and the bio-pharmaceutical industry is only in the temple of heaven and Shanghai.
Net profit margin TOP20
In the first half of the year, tiantan creatures, Shanghai leishi and jilin aodong performed well. The tiantan creature ranked first with a net profit margin of 100.11%, while Shanghai laishi finished second with 81.72%, while jilin aodong's net profit margin of 74.35% came in third.
Sales gross margin TOP20
In the first half of the year, the gross profit margin of four pharmaceutical companies was over 90%, and the top three were my martial creatures, beida and haite. The biopharmaceutical industry has 12.
(source: tongda letter)
|
